[Business Wire] – Alexion Pharmaceuticals, Inc. announced today that researchers presented new data from an ongoing open-label, Phase 1/2 trial of intravenous SBC-103 , an investigational enzyme replacement therapy, in children with mucopolysaccharidosis IIIB , a genetic, progressive, and devastating rare lysosomal storage disease. Read more on this. , valued at $ecting to http://finance.ya, finished at $. Looking at the stock, its one day range is $ and has traded between $ over the past year. ALXN shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x earnings multiple. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $, which would be a $0.00 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d ALXN from to (/fin). Previously, d ALXN from to . When considering if perhaps the stock is under or overvalued, the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NASDAQ:ALXN) Similar Articles: Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. — ALXN Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016